Ht-Logo-gigapixel-icon
Search
Close this search box.
Ht-Logo-gigapixel-icon
Search
Close this search box.
Sunday, December 22, 2024
Canada’s Politics and Government News Source Since 1989
Latest Paper
Sunday, December 22, 2024 | Latest Paper
Subscribe Now

TRENDING:

Ruth Ross

Ruth Ross, PhD, is chair of the Department of Pharmacology & Toxicology, director of the Centre for Collaborative Drug Research at the University of Toronto, and has conducted research on cannabis and the endocannabinoid system for over 20 years.

Questions that need answers: research needs to keep pace with escalating cannabis issues

  • As a seasoned researcher in the field of cannabis and cannabinoid pharmacology, there are a few key areas where the current lack of information
Opinion | BY RUTH ROSS | October 28, 2020
One of the pharmacology questions left to be answered is about the use of CDB, writes Ruth Ross who says that while there is good data on the use of CBD as a medicine for epilepsy in children, these trials and others have highlighted potential effects of CBD on the liver and in modifying the levels of other medications that patients may be taking. Pexels photograph by Elsa Olofsson, cbdoracle.com

Questions that need answers: research needs to keep pace with escalating cannabis issues

Opinion | BY RUTH ROSS | October 28, 2020
  • As a seasoned researcher in the field of cannabis and cannabinoid pharmacology, there are a few key areas where the current lack of information

Questions that need answers: research needs to keep pace with escalating cannabis issues

Opinion | BY RUTH ROSS | October 28, 2020
  • As a seasoned researcher in the field of cannabis and cannabinoid pharmacology, there are a few key areas where the current lack of information
One of the pharmacology questions left to be answered is about the use of CDB, writes Ruth Ross who says that while there is good data on the use of CBD as a medicine for epilepsy in children, these trials and others have highlighted potential effects of CBD on the liver and in modifying the levels of other medications that patients may be taking. Pexels photograph by Elsa Olofsson, cbdoracle.com

Cannabis legalization: good intentions, but is it good policy?

  • The recently introduced legislation to legalize nonmedical use of cannabis follows reasonably closely the recommendations of the task force set up last year to
Opinion | BY HAROLD KALANT, RUTH ROSS | July 10, 2017
The Canopy Growth Corporation, a cannabis company in Smiths Falls, Ont. The government has the option to proceed incrementally: decriminalize possession now, monitor effects of legalization elsewhere, do the much-needed research to fill major gaps in our knowledge, and then make a rationally based decision on legalization. The Hill Times photograph by Jake Wright

Cannabis legalization: good intentions, but is it good policy?

Opinion | BY HAROLD KALANT, RUTH ROSS | July 10, 2017
  • The recently introduced legislation to legalize nonmedical use of cannabis follows reasonably closely the recommendations of the task force set up last year to

Cannabis legalization: good intentions, but is it good policy?

Opinion | BY HAROLD KALANT, RUTH ROSS | July 10, 2017
  • The recently introduced legislation to legalize nonmedical use of cannabis follows reasonably closely the recommendations of the task force set up last year to
The Canopy Growth Corporation, a cannabis company in Smiths Falls, Ont. The government has the option to proceed incrementally: decriminalize possession now, monitor effects of legalization elsewhere, do the much-needed research to fill major gaps in our knowledge, and then make a rationally based decision on legalization. The Hill Times photograph by Jake Wright
More Stories

News

Get free news updates

Opinion

Submit a guest opinion article

resources

Follow us

Advertise

get help

Subscribe
CloseMenu